Global Ewing Sarcoma Drugs Market Forecast
- Global Ewing sarcoma drugs market set to rise high at a promising CAGR of 5% during 2023 - 2030
- Market valuation likely to reach US$0.3 billion in revenue by 2030-end
Market Analysis in Brief
The global Ewing sarcoma drugs market is the pharmaceutical market focused on developing and commercialising drugs for treating Ewing sarcoma, an aggressive form of bone cancer primarily affecting children and young adults. Ewing sarcoma is a type of cancer that arises in the bones or soft tissues, typically affecting adolescents and young adults. It is characterised by a specific genetic abnormality called the EWSR1-FLI1 fusion gene. Due to the rarity of Ewing sarcoma and its aggressive nature, treatment options have historically been limited. The standard treatment typically involves a combination of surgery, chemotherapy, and radiation therapy.
Despite advancements in cancer research, there remains an unmet medical need for more effective and targeted treatments tailored for Ewing sarcoma patients. Pharmaceutical companies and research institutions continue to explore and develop novel drugs to target the genetic drivers of Ewing sarcoma. Clinical trials analyse the safety and efficacy of potential new treatments. The market for Ewing sarcoma drugs is expected to grow as new therapies and targeted treatments emerge. The demand for more effective and less toxic treatments for Ewing sarcoma patients drives drug development in this field.
Key Report Findings
- Drug development for rare diseases like Ewing sarcoma often benefits from regulatory incentives and expedited pathways, such as orphan drug designation.
- Demand for Ewing sarcoma for bone tumours remains higher in the Ewing sarcoma drugs market.
- The chemotherapy category held the highest share of the Ewing sarcoma drugs market revenue in 2022.
- North America will continue to lead, whereas the Asia Pacific Ewing sarcoma drugs market will experience the strongest growth till 2030.
Growth Drivers
Advancements in Cancer Research
Advancements in cancer research play a pivotal role in driving the market's growth for cancer drugs, including those targeting Ewing sarcoma. These advancements significantly impact various market aspects, improving treatment options, patient outcomes, and overall market expansion.
Cancer research has identified specific genetic mutations and molecular pathways that drive the growth of cancer cells, including those in Ewing sarcoma. This knowledge has led to the development of targeted therapies designed to inhibit these specific targets. Targeted therapies are more precise and less toxic than traditional chemotherapy, improving efficacy and reducing patient side effects.
Advancements in cancer research have enabled a deeper understanding of individual tumour’s genetic and molecular profiles. This knowledge allows for personalised treatment approaches, where therapies are tailored to the unique characteristics of a patient's cancer. Personalised medicine has the potential to increase treatment effectiveness and improve patient outcomes.
Cancer research has identified biomarkers, measurable indicators of a patient's disease state or response to treatment. Biomarkers help in patient selection for clinical trials and can be used for monitoring treatment effectiveness. They also aid in identifying patients who are most likely to benefit from specific therapies, leading to more efficient drug development and clinical trial design.
As advancements in cancer research continue, understanding cancer biology, identifying therapeutic targets, and developing innovative treatment approaches will likely drive further market growth. Additionally, the increasing focus on precision medicine and personalised therapies is expected to shape the future of cancer drug development and improve outcomes for patients with Ewing sarcoma, and other types of cancer.
Growing Prevalence of Ewing Sarcoma
The growing prevalence of Ewing sarcoma is a significant driver for the market growth of Ewing sarcoma drugs. As the incidence of Ewing sarcoma increases, there is a greater demand for effective treatment options, leading to increased investment in research, drug development, and commercialisation. With more individuals diagnosed with Ewing sarcoma, the patient pool seeking treatment expands. This larger patient base allows pharmaceutical companies to develop and market drugs targeted at Ewing sarcoma.
As awareness about Ewing sarcoma increases among healthcare professionals and the public, more cases are diagnosed at early stages. Early diagnosis allows for timely initiation of treatment, potentially improving patient outcomes and driving the need for effective drugs. The growing prevalence of Ewing sarcoma attracts greater attention from the medical and research communities, resulting in increased research funding and investment in drug development. This contributes to the advancement of potential new therapies and treatment options.
The rising prevalence of Ewing sarcoma may qualify the disease for orphan drug status in some regions. Regulatory agencies often provide incentives and faster review processes for orphan drugs, encouraging pharmaceutical companies to invest in drug development for rare diseases like Ewing sarcoma.
With an increasing focus on healthcare infrastructure development in many regions, there is a growing emphasis on enhancing oncology facilities and providing access to advanced treatment options, including Ewing sarcoma drugs. The growing prevalence of Ewing sarcoma brings attention to the urgent need for effective treatments, spurring research, drug development, and investment in the market for Ewing sarcoma drugs. As advancements continue in understanding the disease and developing novel therapies, the market is expected to expand to meet the needs of patients with Ewing sarcoma.
Overview of Key Segments
Application in Chemotherapy to Increase
The rise in the application of Ewing sarcoma drugs for chemotherapy drives the market. As the application of Ewing sarcoma drugs for chemotherapy increases, there is a higher demand for these drugs in the market. The growing number of Ewing sarcoma cases and the use of chemotherapy as a standard treatment drive the need for these drugs.
Ewing sarcoma treatment often involves a combination of chemotherapy drugs to achieve better treatment outcomes. The use of multiple drugs in combination creates a broader market for Ewing sarcoma drugs. Chemotherapy is an established and widely accepted treatment option for Ewing sarcoma. Its recognition as a standard of care ensures a steady demand for chemotherapy drugs, contributing to market growth.
Ongoing research and clinical trials exploring new chemotherapy agents and combinations to improve treatment efficacy has led to the development of new drugs. Successful trial outcomes and regulatory approvals expand the range of available drugs in the market. Despite advances in other treatment modalities, chemotherapy remains a crucial treatment option for Ewing sarcoma, particularly in certain cases, such as metastatic disease.
The unmet medical need for effective treatments drives the demand for chemotherapy drugs. Research and development efforts have led to the development of more targeted and less toxic chemotherapy drugs for Ewing sarcoma. These targeted drugs improve treatment outcomes and patient quality of life, further driving their adoption in the market.
As the understanding of Ewing sarcoma biology and treatment approaches continues to advance, and with ongoing research in the field of oncology, the role of chemotherapy and other targeted therapies is expected to evolve. The market for Ewing sarcoma drugs will likely expand as new drugs and treatment modalities are developed, offering better treatment options and improved patient outcomes.
Hospitals Hold Maximum Opportunities
Hospitals are the primary end users of Ewing sarcoma drugs. They offer a broad range of medical services, which include cancer treatment, and often have specialised oncology departments equipped to administer chemotherapy and other Ewing sarcoma drugs.
Specialised cancer treatment centres provide comprehensive care for patients with rare and complex diseases like Ewing sarcoma. These centres often have dedicated teams of oncologists and support staff experienced in managing Ewing sarcoma cases. Ewing sarcoma affects children and young adults.
Paediatric hospitals and centres play a crucial role in treating paediatric Ewing sarcoma patients, providing specialised care specific to the unique needs of young patients. Oncology clinics, both standalone facilities and those within hospitals, are important end users of Ewing sarcoma drugs. They offer outpatient care and administer chemotherapy and other cancer treatments to patients with Ewing sarcoma.
Research institutions conducting clinical trials and preclinical studies on Ewing sarcoma drugs also serve as end users. These institutions are involved in testing the safety and efficacy of new drug candidates to advance the field of Ewing sarcoma treatment.
Ultimately, the patients and their caregivers are end users of Ewing sarcoma drugs. They play a central role in the treatment process, following treatment plans, adhering to drug regimens, and managing potential side effects under healthcare professionals' guidance. With the rise in cases of Ewing Sarcoma disease, hospitals' demand for Ewing sarcoma drugs is expected to grow significantly during the forecast period.
Growth Opportunities Across Regions
North America Spearheads, Has Several Drugs in Pipeline
North America dominated the global Ewing sarcoma drugs market in 2022. North America has well-developed, advanced healthcare infrastructure, including state-of-the-art hospitals, cancer treatment centres, and research institutions. This facilitates Ewing sarcoma cases' diagnosis, treatment, and management, increasing drug demand. The region is at the forefront of clinical research and drug development.
North America hosts numerous clinical trials evaluating new Ewing sarcoma drugs and treatment approaches, attracting domestic and international patients. The regulatory agencies in North America, such as the US Food and Drug Administration (FDA) and Health Canada, have processes that encourage drug development for rare diseases like Ewing sarcoma.
Orphan drug designations and expedited review pathways support the development and approval of new drugs. The incidence of Ewing sarcoma is relatively high in North America compared to other regions. The prevalence of the disease drives the demand for effective treatment options, including Ewing sarcoma drugs. North America is home to several major pharmaceutical and biotech firms investing in oncology drug development, including drugs for rare diseases like Ewing sarcoma.
Moreover, the North American region has numerous well-established oncology centres with experienced oncologists specialising in treating bone tumours and sarcomas. Also, North America has a relatively high healthcare spending, allowing for greater affordability and access to advanced treatments, including Ewing sarcoma drugs, leading the region in the global landscape of Ewing sarcoma drugs.
Asia Pacific Grows Significantly with Rising Disease Prevalence
The market for Ewing sarcoma drugs across Asia will display a significant CAGR over the forecast period. Ewing sarcoma has been increasing in Asia like other parts of the world. This rising disease prevalence creates a larger patient pool, increasing demand for effective treatment options, including Ewing sarcoma drugs.
Many nations in Asia are investing significantly in their healthcare infrastructure, including establishing specialised oncology centres and cancer treatment facilities. This development enhances patient access to advanced treatments and increases the demand for Ewing sarcoma drugs. The Asia Pacific region has witnessed growth in oncology research and clinical trials.
Pharmaceutical companies are increasingly conducting clinical trials for Ewing sarcoma drugs in the region, making innovative therapies more accessible to patients. Regulatory agencies in Asia have been streamlining approval processes and providing incentives for drug developers to address the unmet medical needs of rare diseases like Ewing sarcoma. This has encouraged investment in drug development and commercialisation in the region.
Patient advocacy groups and organisations in the Asia Pacific have been working to raise awareness about Ewing sarcoma and improve treatment access. Their efforts have led to greater recognition of the disease and the need for effective drugs. In addition, the economic growth in several countries within the Asia Pacific region has led to increased affordability of healthcare services, making advanced treatments, including Ewing sarcoma drugs, more accessible to patients.
Growth Challenges
High Development Costs
The high development costs for Ewing sarcoma drugs are a significant restraint for the market. Developing new drugs, especially those targeting rare diseases like Ewing sarcoma, involves substantial financial investments and resources. The high development costs present challenges for pharmaceutical companies and the market's growth. The relatively small patient population with Ewing sarcoma means the potential market size for these drugs is limited. As a result, the ROI for pharmaceutical companies investing in drug development for Ewing sarcoma may be lower compared to drugs targeting more prevalent diseases.
The process of drug development for rare diseases can be time-consuming and complex. It may take several years of research, preclinical studies, and clinical trials before a drug is approved for commercialisation. This prolonged development timeline increases costs and delays the availability of new treatments to patients.
Conducting clinical trials for Ewing sarcoma drugs requires a significant financial investment. Recruiting and enrolling enough patients for clinical trials and ensuring compliance with regulatory requirements add to the overall expenses. Drug development is inherently risky, with a high failure rate during clinical trials. Even if substantial investments are made in research and development, there is no guarantee that a drug will successfully progress through the clinical trial phases and receive regulatory approval.
Moreover, the high development costs and risks associated with rare diseases like Ewing sarcoma sometimes lead to investor concerns and reluctance to fund drug development programs, potentially limiting the availability of capital for such initiatives, which may hamper the growth of Ewing sarcoma drugs during the forecast period.
Ewing Sarcoma Drugs Market: Competitive Landscape
Some of the leading players at the forefront in the Ewing sarcoma drugs market space include Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Novartis AG, Johnson and Johnson, Inc., Abbott Laboratories, GlaxoSmithKline plc, Bayer AG, AstraZeneca, and Pfizer Inc.
Recent Notable Developments
In July 2023, GlaxoSmithKline plc publicised that the Niraparib drug was under clinical development and is currently in Phase II for Ewing Sarcoma. Niraparib (MK-4827, Zejula) is an anti-neoplastic agent. It is formulated as hard gelatin capsules, tablets, and film-coated tablets for oral administration.
In May 2023, The U.S. FDA allowed Salarius to resume recruitment for a Phase I/II study (NCT03600649) testing its lead candidate seclidemstat in the rare paediatric cancer Ewing sarcoma. Previously, Salarius paused enrollment in October 2022 due to an unexpected patient death, which was classified as a suspected unexpected serious adverse reaction (SUSAR).
In April 2023, Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, received an orphan drug designation from the U.S. FDA for TP-1287, an investigational oral CDK9 inhibitor, for the treatment of Ewing sarcoma.
The Global Ewing Sarcoma Drugs Market is Segmented as Below:
By Tumour Type
- Bone Tumour
- Peripheral Primitive Neuroectodermal Tumour
- Askin Tumour
- Soft Tissue Tumour
By Application
- Chemotherapy
- Surgery
- Radiation
- Others
By End User
- Hospital
- Specialty Clinic
- Homecare
- Others
By Geographic Coverage
- North America
- The U.S.
- Canada
- Europe
- Germany
- The U.K.
- France
- Italy
- Turkey
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Egypt
- Nigeria
- Rest of the Middle East & Africa
1. Executive Summary
1.1. Global Ewing Sarcoma Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Ewing Sarcoma Treatment Market Outlook, 2018 - 2030
3.1. Global Ewing Sarcoma Treatment Market Outlook, by Tumour Type, Value (US$ Bn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Bone Tumour
3.1.1.2. Peripheral Primitive Neuroectodermal Tumour
3.1.1.3. Askin Tumour
3.1.1.4. Soft Tissue Tumour
3.2. Global Ewing Sarcoma Treatment Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
3.2.1. Key Highlights
3.2.1.1. Chemotherapy
3.2.1.2. Surgery
3.2.1.3. Radiation
3.2.1.4. Others
3.3. Global Ewing Sarcoma Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
3.3.1. Key Highlights
3.3.1.1. Hospital
3.3.1.2. Specialty Clinic
3.3.1.3. Homecare
3.3.1.4. Others
3.4. Global Ewing Sarcoma Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Ewing Sarcoma Treatment Market Outlook, 2018 - 2030
4.1. North America Ewing Sarcoma Treatment Market Outlook, by Tumour Type, Value (US$ Bn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Bone Tumour
4.1.1.2. Peripheral Primitive Neuroectodermal Tumour
4.1.1.3. Askin Tumour
4.1.1.4. Soft Tissue Tumour
4.2. North America Ewing Sarcoma Treatment Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Chemotherapy
4.2.1.2. Surgery
4.2.1.3. Radiation
4.2.1.4. Others
4.3. North America Ewing Sarcoma Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. Hospital
4.3.1.2. Specialty Clinic
4.3.1.3. Homecare
4.3.1.4. Others
4.3.2. Market Attractiveness Analysis
4.4. North America Ewing Sarcoma Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
4.4.1. Key Highlights
4.4.1.1. U.S. Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
4.4.1.2. U.S. Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
4.4.1.3. U.S. Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
4.4.1.4. Canada Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
4.4.1.5. Canada Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
4.4.1.6. Canada Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Ewing Sarcoma Treatment Market Outlook, 2018 - 2030
5.1. Europe Ewing Sarcoma Treatment Market Outlook, by Tumour Type, Value (US$ Bn), 2018 - 2030
5.1.1. Key Highlights
5.1.1.1. Bone Tumour
5.1.1.2. Peripheral Primitive Neuroectodermal Tumour
5.1.1.3. Askin Tumour
5.1.1.4. Soft Tissue Tumour
5.2. Europe Ewing Sarcoma Treatment Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
5.2.1. Key Highlights
5.2.1.1. Chemotherapy
5.2.1.2. Surgery
5.2.1.3. Radiation
5.2.1.4. Others
5.3. Europe Ewing Sarcoma Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
5.3.1. Key Highlights
5.3.1.1. Hospital
5.3.1.2. Specialty Clinic
5.3.1.3. Homecare
5.3.1.4. Others
5.3.2. Market Attractiveness Analysis
5.4. Europe Ewing Sarcoma Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
5.4.1. Key Highlights
5.4.1.1. Germany Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.2. Germany Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.3. Germany Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.1.4. U.K. Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.5. U.K. Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.6. U.K. Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.1.7. France Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.8. France Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.9. France Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.1.10. Italy Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.11. Italy Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.12. Italy Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.1.13. Turkey Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.14. Turkey Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.15. Turkey Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.1.16. Russia Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.17. Russia Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.18. Russia Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.1.19. Rest of Europe Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
5.4.1.20. Rest of Europe Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
5.4.1.21. Rest of Europe Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Ewing Sarcoma Treatment Market Outlook, 2018 - 2030
6.1. Asia Pacific Ewing Sarcoma Treatment Market Outlook, by Tumour Type, Value (US$ Bn), 2018 - 2030
6.1.1. Key Highlights
6.1.1.1. Bone Tumour
6.1.1.2. Peripheral Primitive Neuroectodermal Tumour
6.1.1.3. Askin Tumour
6.1.1.4. Soft Tissue Tumour
6.2. Asia Pacific Ewing Sarcoma Treatment Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
6.2.1. Key Highlights
6.2.1.1. Chemotherapy
6.2.1.2. Surgery
6.2.1.3. Radiation
6.2.1.4. Others
6.3. Asia Pacific Ewing Sarcoma Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
6.3.1. Key Highlights
6.3.1.1. Hospital
6.3.1.2. Specialty Clinic
6.3.1.3. Homecare
6.3.1.4. Others
6.3.2. Market Attractiveness Analysis
6.4. Asia Pacific Ewing Sarcoma Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
6.4.1. Key Highlights
6.4.1.1. China Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
6.4.1.2. China Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
6.4.1.3. China Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
6.4.1.4. Japan Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
6.4.1.5. Japan Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
6.4.1.6. Japan Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
6.4.1.7. South Korea Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
6.4.1.8. South Korea Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
6.4.1.9. South Korea Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
6.4.1.10. India Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
6.4.1.11. India Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
6.4.1.12. India Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
6.4.1.13. Southeast Asia Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
6.4.1.14. Southeast Asia Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
6.4.1.15. Southeast Asia Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
6.4.1.16. Rest of Asia Pacific Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
6.4.1.17. Rest of Asia Pacific Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
6.4.1.18. Rest of Asia Pacific Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Ewing Sarcoma Treatment Market Outlook, 2018 - 2030
7.1. Latin America Ewing Sarcoma Treatment Market Outlook, by Tumour Type, Value (US$ Bn), 2018 - 2030
7.1.1. Key Highlights
7.1.1.1. Bone Tumour
7.1.1.2. Peripheral Primitive Neuroectodermal Tumour
7.1.1.3. Askin Tumour
7.1.1.4. Soft Tissue Tumour
7.2. Latin America Ewing Sarcoma Treatment Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
7.2.1. Key Highlights
7.2.1.1. Chemotherapy
7.2.1.2. Surgery
7.2.1.3. Radiation
7.2.1.4. Others
7.3. Latin America Ewing Sarcoma Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
7.3.1. Key Highlights
7.3.1.1. Hospital
7.3.1.2. Specialty Clinic
7.3.1.3. Homecare
7.3.1.4. Others
7.3.2. Market Attractiveness Analysis
7.4. Latin America Ewing Sarcoma Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
7.4.1. Key Highlights
7.4.1.1. Brazil Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
7.4.1.2. Brazil Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
7.4.1.3. Brazil Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
7.4.1.4. Mexico Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
7.4.1.5. Mexico Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
7.4.1.6. Mexico Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
7.4.1.7. Argentina Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
7.4.1.8. Argentina Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
7.4.1.9. Argentina Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
7.4.1.10. Rest of Latin America Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
7.4.1.11. Rest of Latin America Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
7.4.1.12. Rest of Latin America Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Ewing Sarcoma Treatment Market Outlook, 2018 - 2030
8.1. Middle East & Africa Ewing Sarcoma Treatment Market Outlook, by Tumour Type, Value (US$ Bn), 2018 - 2030
8.1.1. Key Highlights
8.1.1.1. Bone Tumour
8.1.1.2. Peripheral Primitive Neuroectodermal Tumour
8.1.1.3. Askin Tumour
8.1.1.4. Soft Tissue Tumour
8.2. Middle East & Africa Ewing Sarcoma Treatment Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
8.2.1. Key Highlights
8.2.1.1. Chemotherapy
8.2.1.2. Surgery
8.2.1.3. Radiation
8.2.1.4. Others
8.3. Middle East & Africa Ewing Sarcoma Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
8.3.1. Key Highlights
8.3.1.1. Hospital
8.3.1.2. Specialty Clinic
8.3.1.3. Homecare
8.3.1.4. Others
8.3.2. Market Attractiveness Analysis
8.4. Middle East & Africa Ewing Sarcoma Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
8.4.1. Key Highlights
8.4.1.1. GCC Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
8.4.1.2. GCC Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
8.4.1.3. GCC Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
8.4.1.4. South Africa Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
8.4.1.5. South Africa Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
8.4.1.6. South Africa Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
8.4.1.7. Egypt Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
8.4.1.8. Egypt Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
8.4.1.9. Egypt Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
8.4.1.10. Nigeria Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
8.4.1.11. Nigeria Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
8.4.1.12. Nigeria Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
8.4.1.13. Rest of Middle East & Africa Ewing Sarcoma Treatment Market by Tumour Type, Value (US$ Bn), 2018 - 2030
8.4.1.14. Rest of Middle East & Africa Ewing Sarcoma Treatment Market Type, Value (US$ Bn), 2018 - 2030
8.4.1.15. Rest of Middle East & Africa Ewing Sarcoma Treatment Market by End User, Value (US$ Bn), 2018 - 2030
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Manufacturer vs Type Heatmap
9.2. Company Market Share Analysis, 2022
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Merck & Co., Inc.
9.4.1.1. Company Overview
9.4.1.2. Tumour Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. F. Hoffmann-La Roche Ltd.
9.4.2.1. Company Overview
9.4.2.2. Tumour Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Bristol-Myers Squibb Company
9.4.3.1. Company Overview
9.4.3.2. Tumour Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Novartis AG
9.4.4.1. Company Overview
9.4.4.2. Tumour Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Johnson and Johnson, Inc.
9.4.5.1. Company Overview
9.4.5.2. Tumour Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Abbott Laboratories
9.4.6.1. Company Overview
9.4.6.2. Tumour Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. GlaxoSmithKline plc
9.4.7.1. Company Overview
9.4.7.2. Tumour Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Bayer AG
9.4.8.1. Company Overview
9.4.8.2. Tumour Portfolio
9.4.8.3. Business Strategies and Development
9.4.9. AstraZeneca
9.4.9.1. Company Overview
9.4.9.2. Tumour Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Pfizer, Inc.
9.4.10.1. Company Overview
9.4.10.2. Tumour Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations
|
BASE YEAR |
HISTORICAL DATA |
FORECAST PERIOD |
UNITS |
|||
 |
2022 |
 |
2018 - 2022 |
 |
2023 - 2030 |
Value: US$ Million |
|
REPORT FEATURES |
DETAILS |
|
Tumour Type Coverage |
|
|
Application Coverage |
|
|
End User Coverage |
|
|
Geographical Coverage |
|
|
Leading Companies |
|
|
Report Highlights |
Key Market Indicators, Macro-micro economic impact analysis, Technological Roadmap, Key Trends, Driver, Restraints, and Future Opportunities & Revenue Pockets, Porter’s 5 Forces Analysis, Historical Trend (2019-2021), Market Estimates and Forecast, Market Dynamics, Industry Trends, Competition Landscape, Category, Region, Country-wise Trends & Analysis, COVID-19 Impact Analysis (Demand and Supply Chain) |
Quality assured
